D. DO NOT COMPLY WITH PERFORMANCE STANDARDS; ARE HELD AND WILL REMAIN UNDER BOND; AND WILL NOT BE. INTRODUCED INTO COMMERCE UNTIL NOTIFICATION IS RECEIVED FROM FDA THAT PRODUCTS HAVE BEEN BROUGHT. INTO COMPLIANCE IN ACCORDANCE WITH AN FDA APPROVED PETITION.
HHMI researchers identify gene mutations that cause a potentially fatal clotting disorder. Researchers have determined the cause of a potentially deadly inherited blood-clotting disorder that can lead to kidney failure or stroke. The researchers found that the disorder, thrombotic thrombocytopenic purpura (TTP), is caused by mutations in a gene that render the ADAMTS13 enzyme ineffective.
Idiopathic thrombocytopenic purpura (ITP) is a rare autoimmune disorder. The personâs blood does not clot properly because antibodies destroy the platelets that help blood to clot. Blood is partly made up of platelets (thrombocytes) â small, cell-like bodies that are important in blood clotting.